COPD – media

Status quo analysis of lung diseases with necessity of pulmonary function tests

According to the World Health Organization, more than half (54%) of the world's 56.4 million deaths in 2015 were caused by ten major health issues including heart disease, accidents and cardiovascular-cerebrovascular diseases.
- Source: Ddu
- 1,186
- September 6, 2018
Company Insight COPD Drugdu.com
Asthma + COPD = ACOS

As pollution increases, so do diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma patients face difficulty in breathing due to the narrowing of airways caused by inflammation. COPD patients, however, can be affected with chronic bronchitis which leads to restrained breathing.
- Source: Reuters
- 1,027
- August 24, 2018
ACOs asthma Asthma and COPD Overlap Syndrome COPD Researches
Enquiry for Nucala in COPD

Nucala (mepolizumab) was first approved as the first anti-IL5 treatment for adults and adolescents with severe asthma accompanied by eosinophilic phenotype in the United States during November 2015. Later it was approved to treat eosinophilic granulomatosis with polyangiitis (EGPA).
- Source: BioPharmaDive
- 773
- July 26, 2018
COPD GSK New Approvals
COPD Assessment by CT Analysis

Chronic Obstructive Pulmonary Disease (COPD) is defined as a condition which affects airways and alveoli, leading to the loss of lung function in a progressive manner. COPD is the fourth leading cause of death globally and has affected more than 200 million people throughout the world.
- Source: IndiaTimes
- 2,058
- July 2, 2018
COPD medical device Researches
What is COPD and how is it Treated?

Chronic obstructive pulmonary disease (COPD) is kind of lung disorder where the person may have difficulty in breathing which worsens over time. An irritation or inflammation in the lungs causes the air sacs to lose their elasticity, which leaves the air trapped in the lungs when you exhale. If this lasts too long, it could lead to a group of lung diseases (Chronic bronchitis and Emphysema) known as COPD.
- Source: HealthLine
- 690
- June 19, 2018
Clinical Trials COPD
Faron shares almost crashed 90% on Traumakine failure

Finland pharmaceuticals company Faron (AIM: FARN) has crashed almost 90% of its shares, as the company announced the Phase III INTEREST trial of traumakine failed to meet its efficacy endpoint.
- Source: Ddu
- 681
- May 11, 2018
COPD Researches
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.
- Source: us.gsk
- 642
- April 27, 2018
Company Insights COPD FDA GSK
Adherium receives OTC clearance for AstraZeneca’s Symbicort inhaler

Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called the SmartTouch for Symbicort.
- Source: MobiHealthNews
- 801
- April 7, 2018
COPD FDA New Approvals
Artificial Intelligence powers new lung health app

Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK’s innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease.
- Source: Business Weekly
- 620
- March 19, 2018
AI COPD Researches respiratory
Novartis’ Ultibro Breezhaler reduces lung hyperinflation in COPD patients

Treatment with Novartis’ Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show.
- Source: Pharmatimes
- 607
- February 24, 2018
Company Insight COPD Ultibro Breezhaler

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.